In a small study, vitamin K2 supplementation in CKD stages 3–5 patients reduced the progression of atherosclerosis and significantly changed the levels of calcification promoters and inhibitors: dp-ucMGP, osteocalcin, and osteoprotegerin [98]. This evidence concerns the gene BGLAP and chronic kidney disease.